Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Clinical Trials
•
Pediatric Oncology
•
Oncology
What are the main barriers you encounter in enrolling pediatric oncology patients on clinical trials?
Related Questions
How do you approach revaccination after chemotherapy, and what labs (if any) do you use to assess immune reconstitution?
For patients with Stage IIIB or IV HD flowing Bv-AVEPC with initial large mediastinal adenopathy, how can we avoid ISRT?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
How should clinicians approach the decision to use apixaban, or other DOACs, in pediatric patients with acute lymphoblastic leukemia or lymphoma who have additional risk factors for VTE, such as obesity or a family history of thrombosis, given the negative outcome of the PREVAPIX-ALL trial?
If a pediatric patient has a prior history of cancer-associated thrombosis while receiving active treatment, can they be on estrogen-containing OCPs in the future?
Do you use prophylactic defibrotide in pediatric patients undergoing BMT who are considered to be at high risk for the development of VOD/SOS?
How will you treat an uterine embryonal rhabdomyosarcoma with regional node involvement resected to involved parametrial margins?
For what patients/diagnoses do you currently use sodium thiosulfate to reduce the risk of cisplatin associated ototoxicity?
Would you recommend a specific workup or change in management for patients with severe, persistent deficits from methotrexate leukoencephalopathy?
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
